Sale

Diabetic Gastroparesis Treatment Market

Global Diabetic Gastroparesis Treatment Market Size, Research, Report: By Type: Surgical Treatment Products, Drugs; By Disease Indication: Compensated Gastroparesis, Gastric Failure, Others; By End User: Hospitals, Specialty Clinics, Homecare; By Route of Administration: Oral, Injectables; Regional Analysis; Supplier Landscape; 2024-2032

Global Diabetic Gastroparesis Treatment Market Outlook

The global diabetic gastroparesis treatment market size was valued at USD 3.64 billion in 2023, driven by the improvements in the arena of healthcare and gastric treatments. The market is anticipated to grow at a CAGR of 4.1% during the forecast period 2024-2032 to reach a value of USD 5.87 billion by 2032. 

 

Diabetic Gastroparesis Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Advancements in Healthcare and Gastric Treatments to Aid the Market Growth of Diabetic Gastroparesis Treatment

The market for diabetic gastroparesis treatment is being driven by the improvements in the arena of healthcare and gastric treatments. The market is further aided by the growing cases of diabetes across the globe. Further, the existence of a seamless healthcare industry lays emphasis on the swift treatment and diagnosis, which is also propelling the market forward. Diabetic gastroparesis severely affects the quality of life. Therefore, medical practitioners are showing tremendous concern for the patient while treating such disorders, consequently enhancing the market growth. In addition, the availability of dieticians and professionals who can advise the patient regarding proper food consumption and food habits is also contributing to the market growth of diabetic gastroparesis treatment. All these factors are expected to support the market growth over the forecast period as well.

 

Diabetic Gastroparesis Treatment Market By Distributional Channel

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Diabetic Gastroparesis Treatment: Market Segmentation

Diabetic gastroparesis treatment is the treatment for delayed gastric emptying related to diabetes. The condition is observed in patients suffering from type-1 and type-2 diabetes and is found to be frequent in female patients that are suffering from type-2 diabetes.

On the basis of type, the market is divided into:

  • Surgical Treatment Products
  • Drugs

Based on disease indication, the industry can be segmented into:

  • Compensated Gastroparesis
  • Gastric Failure
  • Others

By distribution channel, the industry is categorised into:

  • Hospital Pharmacies 
  • Drug Stores
  • Private Clinics
  • Retail Pharmacies
  • Others

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Diabetic Gastroparesis Treatment Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Cases of Diabetes to Aid the Market Growth of Diabetic Gastroparesis Treatment

The diabetic gastroparesis treatment industry is being driven by the need to meet the evolving demands within the diabetic treatment and diagnostics sector. The market is further aided by the rising cases of type-I and type-II diabetes. Furthermore, the rising demand for minimally invasive treatments and surgeries for the diabetic gastroparesis is also providing an impetus to the market growth as it has created significant growth opportunities within the industry. Moreover, the development of new drug lines within the industry is expected to boost the market growth of diabetic gastroparesis treatment over the forecast period.

 

Key Industry Players in the Global Diabetic Gastroparesis Treatment Market

The report gives a detailed analysis of the following key players in the global diabetic gastroparesis treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Evoke Pharma, Inc.
  • Allergan plc
  • Salix Pharmaceuticals
  • Theravance Biopharma, Inc.
  • Medtronic, plc 
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Disease Indication
  • End User
  • Route of Administration
  • Region
Breakup by Type
  • Surgical Treatment Products
  • Drugs
Breakup by Disease Indication
  • Compensated Gastroparesis
  • Gastric Failure
  • Others
Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Homecare
Breakup by Route of Administration
  • Oral
  • Injectables
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Evoke Pharma Inc.
  • Allergen Pnc.
  • Salix Pharmaceuticals
  • Theravance Biopharma Inc.
  • Medtronics pLC
  • Abbot
  • Rhythm Pharmaceuticals
  • Allergen plc.
  • Astrazeneca plc.
  • Cadila Pharmaceuticals
  • Neurogastrx Inc
  • Bausch Health
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Diabetic Gastroparesis Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Diabetic Gastroparesis Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Diabetic Gastroparesis Epidemiology (2016-2031)
    5.3    Europe Diabetic Gastroparesis Epidemiology (2016-2031)
    5.4    Asia-Pacific Diabetic Gastroparesis Epidemiology (2016-2031)
    5.5    Latin America Diabetic Gastroparesis Epidemiology (2016-2031)
    5.6    Middle East & Africa Diabetic Gastroparesis Epidemiology (2016-2031)
6    Diabetic Gastroparesis Treatment Market Overview 
    6.1    Diabetic Gastroparesis Treatment Market Historical Value (2017-2023) 
    6.2    Diabetic Gastroparesis Treatment Market Forecast Value (2024-2032)
7    Diabetic Gastroparesis Treatment Market Landscape
    7.1    Diabetic Gastroparesis Treatment: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Diabetic Gastroparesis Treatment Product Landscape
        7.2.1    Analysis by Treatment Type
        7.2.2    Analysis by Route of Administration
        7.2.3    Analysis by End User
8    Diabetic Gastroparesis Treatment Market Dynamics
    8.1    Market Drivers and Constraints
    8.2    SWOT Analysis
    8.3    Porter’s Five Forces Model
    8.4    Key Demand Indicators 
    8.5    Key Price Indicators
    8.6    Industry Events, Initiatives, and Trends  
    8.7    Value Chain Analysis
9    Diabetic Gastroparesis Treatment Market Segmentation
    9.1    Diabetic Gastroparesis Treatment Market by Type
        9.1.1    Market Overview
        9.1.2    Surgical Treatment Products
        9.1.3    Drugs
    9.2    Diabetic Gastroparesis Treatment Market by Disease Indication
        9.2.1    Market Overview
        9.2.2    Compensated Gastroparesis
        9.2.3    Gastric Failure
        9.2.4    Others
    9.3    Global Gastroparesis Treatment Market by End User
        9.3.1    Market Overview
        9.3.2    Hospitals
        9.3.3    Specialty Clinics
        9.3.4    Homecare
    9.4    Global Gastroparesis Treatment Market by Route of Administration
        9.4.1    Market Overview
        9.4.2    Oral
        9.4.3    Injectables
    9.5    Diabetic Gastroparesis Treatment Market by Region
        9.5.1    Market Overview
        9.5.2    North America
        9.5.3    Europe 
        9.5.4    Asia Pacific
        9.5.5    Latin America
        9.5.6    Middle East and Africa
10    North America Diabetic Gastroparesis Treatment 
    10.1    Market Share by Country
    10.2    United States of America
    10.3    Canada
11    Europe Diabetic Gastroparesis Treatment 
    11.1    Market Share by Country
    11.2    United Kingdom
    11.3    Germany
    11.4    France
    11.5    Italy
    11.6    Others
12    Asia Pacific Diabetic Gastroparesis Treatment 
    12.1    Market Share by Country
    12.2    China
    12.3    Japan
    12.4    India
    12.5    ASEAN
    12.6    Australia
    12.7    Others
13    Latin America Diabetic Gastroparesis Treatment 
    13.1    Market Share by Country
    13.2    Brazil
    13.3    Argentina
    13.4    Mexico
    13.5    Others
14    Middle East and Africa Diabetic Gastroparesis Treatment 
    14.1    Market Share by Country
    14.2    Saudi Arabia
    14.3    United Arab Emirates
    14.4    Nigeria
    14.5    South Africa
    14.6    Others
15    Regulatory Framework
    15.1    Regulatory Overview
        15.1.1    US FDA
        15.1.2    EU EMA
        15.1.3    INDIA CDSCO
        15.1.4    JAPAN PMDA
        15.1.5    Others
16    Patent Analysis
    16.1    Analysis by Type of Patent
    16.2    Analysis by Publication year
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Patent Age
    16.5    Analysis by CPC Analysis
    16.6    Analysis by Patent Valuation 
    16.7    Analysis by Key Players
17    Grants Analysis
    17.1    Analysis by year
    17.2    Analysis by Amount Awarded
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Grant Application
    17.5    Analysis by Funding Institute
    17.6    Analysis by NIH Departments
    17.7    Analysis by Recipient Organization 
18    Clinical Trials Analysis
    18.1     Analysis by Trial Registration Year
    18.2    Analysis by Trial Status
    18.3    Analysis by Trial Phase
    18.4    Analysis by Therapeutic Area
    18.5    Analysis by Geography
19    Funding and Investment Analysis
    19.1    Analysis by Funding Instances
    19.2    Analysis by Type of Funding
    19.3    Analysis by Funding Amount
    19.4    Analysis by Leading Players
    19.5    Analysis by Leading Investors
    19.6    Analysis by Geography
20    Partnership and Collaborations Analysis
    20.1    Analysis by Partnership Instances
    20.2    Analysis by Type of Partnership
    20.3    Analysis by Leading Players
    20.4    Analysis by Geography
21    Supplier Landscape
    21.1    Evoke Pharma Inc.
        21.1.1    Financial Analysis
        21.1.2    Product Portfolio
        21.1.3    Demographic Reach and Achievements
        21.1.4    Mergers and Acquisitions
        21.1.5    Certifications
    21.2    Allergen Pnc.
        21.2.1    Financial Analysis
        21.2.2    Product Portfolio
        21.2.3    Demographic Reach and Achievements
        21.2.4    Mergers and Acquisitions
        21.2.5    Certifications
    21.3    Salix Pharmaceuticals
        21.3.1    Financial Analysis
        21.3.2    Product Portfolio
        21.3.3    Demographic Reach and Achievements
        21.3.4    Mergers and Acquisitions
        21.3.5    Certifications
    21.4    Theravance Biopharma Inc.
        21.4.1    Financial Analysis
        21.4.2    Product Portfolio
        21.4.3    Demographic Reach and Achievements
        21.4.4    Mergers and Acquisitions
        21.4.5    Certifications
    21.5    Medtronics pLC
        21.5.1    Financial Analysis
        21.5.2    Product Portfolio
        21.5.3    Demographic Reach and Achievements
        21.5.4    Mergers and Acquisitions
        21.5.5    Certifications
    21.6    Abbot
        21.6.1    Financial Analysis
        21.6.2    Product Portfolio
        21.6.3    Demographic Reach and Achievements
        21.6.4    Mergers and Acquisitions
        21.6.5    Certifications
    21.7    Rhythm Pharmaceuticals
        21.7.1    Financial Analysis
        21.7.2    Product Portfolio
        21.7.3    Demographic Reach and Achievements
        21.7.4    Mergers and Acquisitions
        21.7.5    Certifications
    21.8    Allergen plc.
        21.8.1    Financial Analysis
        21.8.2    Product Portfolio
        21.8.3    Demographic Reach and Achievements
        21.8.4    Mergers and Acquisitions
        21.8.5    Certifications
    21.9    Astrazeneca plc.
        21.9.1    Financial Analysis
        21.9.2    Product Portfolio
        21.9.3    Demographic Reach and Achievements
        21.9.4    Mergers and Acquisitions
        21.9.5    Certifications
    21.10    Cadila Pharmaceuticals
        21.10.1    Financial Analysis
        21.10.2    Product Portfolio
        21.10.3    Demographic Reach and Achievements
        21.10.4    Mergers and Acquisitions
        21.10.5    Certifications
    21.11    Neurogastrx Inc
        21.11.1    Financial Analysis
        21.11.2    Product Portfolio
        21.11.3    Demographic Reach and Achievements
        21.11.4    Mergers and Acquisitions
        21.11.5    Certifications
    21.12    Bausch Health
        21.12.1    Financial Analysis
        21.12.2    Product Portfolio
        21.12.3    Demographic Reach and Achievements
        21.12.4    Mergers and Acquisitions
        21.12.5    Certifications
22    Diabetic Gastroparesis Treatment - Distribution Model (Additional Insight)
    22.1    Overview 
    22.2    Potential Distributors 
    22.3    Key Parameters for Distribution Partner Assessment 
23    Key Opinion Leaders (KOL) Insights (Additional Insight)
24    Company Competitiveness Analysis (Additional Insight)

    24.1    Very Small Companies
    24.2    Small Companies
    24.3    Mid-Sized Companies
    24.4    Large Companies
    24.5    Very Large Companies
25    Payment Methods (Additional Insight)
    25.1    Government Funded
    25.2    Private Insurance
    25.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The global diabetic gastroparesis treatment market reached a value of USD 3.64 billion in 2023.

The market is projected to grow at a CAGR of 4.1% during the forecast period of 2024-2032 to reach a value of USD 5.87 billion by 2032.

The major drivers of the industry, such as rising disposable incomes, increasing population, growing improvements in the arena of healthcare and gastric treatments, rising prevalence of diabetes, increasing availability of dieticians and professionals, and growing demand for minimally invasive treatments and surgeries for the diabetic gastroparesis, are expected to aid the market growth.

The key trends guiding the growth of the market include the rising development of new drugs and advancements in the healthcare industry.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific. 

The leading types of diabetic gastroparesis treatment in the industry are surgical treatment products and drugs.

The major disease indications in the market are compensated gastroparesis and gastric failure, among others.

The significant distribution channels in the industry are hospital pharmacies, drug stores, private clinics, and retail pharmacies, among others.

The major players in the industry are Evoke Pharma, Inc., Allergan plc, Salix Pharmaceuticals, Theravance Biopharma, Inc., and Medtronic, plc, among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER